Michael P. Adams - Concepedia

Author

Michael P. Adams

Endo Pharmaceuticals (United States)

Also Known As

Michael Adams, Michael P Adams, Michael P. Adams, Michael Paul Adams

Publications

254

Citations

H-Index

Concepts

All Affiliations

Endo Pharmaceuticals (United States)Prisma Main Line Health

About

Michael P. Adams is an author at Endo Pharmaceuticals (United States) specializing in medicine, pharmacotherapy, and pharmacokinetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	168
2	Health Sciences	1	1	70
3	Social Sciences	1	1	11
4	Biochemistry	1	1	70
5	Metabolism	1	1	70

Michael P. Adams

Publications

246

Citations

H-Index

Page 1

	Year	Citations
Oxymorphone Extended Release Does Not Affect CYP2C9 or CYP3A4 Metabolic Pathways Michael P. Adams, Henry J. Pieniaszek, Arnold R. Gammaitoni, The Journal of Clinical Pharmacology Healthy SubjectsPharmacotherapyExperimental PharmacologyDrug ResistanceMolecular Pharmacology	2005	70
Pharmacokinetics and Dose‐Proportionality of Oxymorphone Extended Release and Its Metabolites: Results of a Randomized Crossover Study Michael P. Adams, Harry Ahdieh Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	2004	65
Single- and Multiple-Dose Pharmacokinetic and Dose-Proportionality Study of??Oxymorphone Immediate-Release Tablets Michael P. Adams, Harry Ahdieh Drugs in R&D Immediate-release TabletsPharmacological StudyPharmacologyPharmacotherapyMedicine	2005	46
Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp James Kulp, Sharon Levy, Melanie Fein, Archives of Dermatological Research Actinic KeratosesFace And/orOphthalmologyImiquimod 3.75Topical Drug	2010	17
Bioequivalence of 2 Intravenous Amiodarone Formulations in Healthy Participants Daniel J. Cushing, Michael P. Adams, Warren D. Cooper, The Journal of Clinical Pharmacology Therapeutic Drug MonitoringNew FormulationCardiovascular DiseaseIntravenous AmiodaroneMedicine	2009	14
Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans Daniel J. Cushing, Paul F. Souney, Warren D. Cooper, Clinical and Experimental Pharmacology and Physiology	2011	13
Comparative Bioavailability of a Premixed, Ready‐to‐Use Formulation of Intravenous Amiodarone With Traditional Admixture in Healthy Subjects Daniel J. Cushing, Michael P. Adams, Warren D. Cooper, The Journal of Clinical Pharmacology Healthy SubjectsIntravenous AmiodaroneCardiovascular PharmacologyPharmacotherapySocial Sciences	2011	11
Evaluation of the Effects of PM101, a Cyclodextrin-Based Formulation of Intravenous Amiodarone, on Blood Pressure in Healthy Humans Daniel J. Cushing, Michael P. Adams, Warren D. Cooper, The American Journal of Cardiology HypertensionHealthy HumansCardiovascular DiseaseCyclodextrin-based FormulationAntihypertensive Therapy	2009	10

Page 1